Pulmonary Hypertension Introduction and Diagnosis

A detailed anatomical illustration showing the cardiovascular and respiratory systems with an emphasis on pulmonary circulation, highlighting arteries, veins, and the heart in a medical context.

Pulmonary Hypertension Quiz

Test your knowledge on pulmonary hypertension with this comprehensive quiz designed for healthcare professionals and students alike. Dive into various aspects of pulmonary circulation, diagnosis, symptoms, and treatment options for pulmonary hypertension.

25 Multiple Choice and Checkboxes questions
Explore cardiovascular and respiratory system components
Understand the latest standards from the World Symposium on Pulmonary Hypertension

25 Questions6 MinutesCreated by AnalyzingData312

Name the major components of cardiovascular system? Choose the correct answer

Heart, Blood, Veins, Arteries

Heart, Veins, Arteries, Arterioles, Capillaries

Name the major components of respiratory system?

Nasal Cavity, Trachea, Bronchi, Bronchioles, Alveoli

Trachea, Bronchi, Alveoli

Pulmonary circulation choose the correct answer

Sup/Inf VC  RA  Mitral Valve  RV  PA  Lungs

Sup/Inf VC  RA  Tricuspid Valve  RV  PV  PA  Lungs

Sup/Inf VC  RA  Tricuspid Valve  RV  PV  Lungs

Sup/Inf VC  RA  Mitral Valve  RV  PV  PA  Lungs

Choose all the correct statements

Arteries, veins and capillaries are consist of 3 layers Tunica Intima, Media and Externa

Arteries and veins are consist of 3 layers Tunica Intima, Media and Externa

Capillaries consists of single cell layer called endothelium

Capillaries consists of two layers called basement membrane and endothelial cells

Arteries consists valves in between to prevent back flow of the blood

Veins consists valves in between to prevent back flow of the blood

Arteries have thick tunica media compare to veins

Veins have thick tunica media compare to arteries

Pulmonary hypertension is a rare lung disorder in which the arteries that carry blood from the heart to the lungs become narrowed, making it difficult for blood to flow through the vessels

True

False

According to 6th WSPH which statement is correct?

Pre-Capillary PH mPAP >20 mmHg, PAWP ≤ 15 mmHg, PVR ≥ 3WU

Pre-Capillary PH mPAP >20 mmHg, PAWP ≥ 15 mmHg, PVR ≤ 3WU

Pre-Capillary PH mPAP ≥ 20 mmHg, PAWP ≤ 15 mmHg, PVR ≥ 3WU

According to 6th WSPH IpcPH is defined as?

MPAP >20 mmHg, PAWP > 15 mmHg, PVR < 3WU

MPAP ≥ 20 mmHg, PAWP ≤ 15 mmHg, PVR > 3 WU

MPAP > 20 mmHg, PAWP <15 mmHg, PVR < 3 WU

According to 6th WSPH CpcPH is defined as?

MPAP >20 mmHg, PAWP > 15 mmHg, PVR < 3WU

MPAP ≥ 20 mmHg, PAWP ≤ 15 mmHg, PVR > 3 WU

MPAP >20 mmHg, PAWP > 15 mmHg, PVR ≥ 3WU

Long-term response to CCBs was defined by clinical improvement (New York Heart Association Functional Class I or II) and sustained haemodynamic improvement after at least 1 year on CCBs only (same or better than achieved in the acute test and usually to obtain mPAP <30 mmHg with an increased or normal CO

True

False

PH associated with congenital heart disease is divided into following 4 groups

Eisenmenger’s syndrome, PAH associated with prevalent systemic to pulmonary shunts, PAH with small/coincidental defects and PAH after defect correction

Eisenmenger’s syndrome, PAH associated with prevalent systemic to pulmonary shunts, PAH with small/coincidental defects and PAH after defect correction, complex congenital heart disease

Eisenmenger’s syndrome, PAH associated with prevalent systemic to pulmonary shunts, PAH with small/coincidental defects and PAH after defect correction, Persistent pulmonary hypertension of newborn

Dysfunctional pulmonary endothelium in PAH is defined as (Choose all correct options)

Altered secretion of pulmonary vasodilators and vasoconstrictors

Changes in proliferative capacity and sensitivity to apoptosis

Pro-inflammatory phenotype

Smooth muscle-like mesenchymal phenotype

Decreased tube formation

Changes in migratory potential

Changes in metabolic processes

Echocardiography remains the most important non-invasive screening tool and right heart catheterization (RHC) remains mandatory to establish the diagnosis.

True

False

After diagnosis of PH and PH group patient should be stratified according to his mortality risk in 1 year to start the appropriate treatment.

True

False

A structured follow up of patient should be carried out after 3-6 months in case of change in therapy and clinical worsening

True

False

Following type of medicines are available to treat PAH

Which statement is correct?

Bosentan has evidence level IA in both WHO FC II and III

Sildenafil has evidence level IA in both WHO FC II and III

Both Bosentan and Sildenafil has evidence level IIb C in WHO FC IV

Beraprost has evidence level IIb B in WHO FC II, III and IV

IV Epoprostenol has evidence level IA in WHO FC III and IV

Pulmonary Hypertension Introduction and Diagnosis

Pulmonary Hypertension Quiz

More Surveys